Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Feb;41(2):469-77.
doi: 10.1016/j.jpainsymman.2010.05.011. Epub 2011 Jan 13.

Additive effects of numbness and muscle aches on fatigue occurrence in individuals with HIV/AIDS who are taking antiretroviral therapy

Affiliations

Additive effects of numbness and muscle aches on fatigue occurrence in individuals with HIV/AIDS who are taking antiretroviral therapy

Dean J Wantland et al. J Pain Symptom Manage. 2011 Feb.

Abstract

Context: Muscle aches, numbness in the feet/toes (neuropathy), and fatigue are often reported concurrently and are among the symptoms most frequently reported by individuals with HIV/AIDS, whether or not they are taking antiretroviral therapy (ART).

Objectives: This study used a longitudinal analytical methodology to analyze these symptoms together to determine whether symptom clusters are maintained over time and to determine whether there is a temporal relationship between fatigue and reports of neuropathic pain and muscle aches.

Methods: This was a secondary analysis of a subset of data from a six-month, longitudinal, randomized, controlled trial of 243 HIV-positive individuals taking ART. Self-reported symptom frequency and intensity were recorded using the Revised Sign and Symptom Checklist for Persons with HIV disease at baseline (Month 0), one, three, and six months. Multilevel, logistic regression models were used to analyze time-lagged effects of muscle aches, numbness of the feet/toes, and fatigue to estimate any predictive and interactive effects that the symptoms have upon one another.

Results: A significant relationship between muscle aches and fatigue intercepts was noted (odds ratio [OR]=1.80, P≤0.05). Significant relationships between numbness and fatigue also were noted for the entire measurement period (OR=2.70, P≤0.05). Time-lagged models showed persons reporting neuropathic-related numbness in one period were nearly twice as likely to report fatigue in subsequent periods (OR=1.89, P≤0.05). The final model revealed that the addition of muscle aches and numbness explained 28% of the random variance in the occurrence of fatigue. Between-person descriptive variables including years living with HIV, age, having an AIDS diagnosis, ethnicity, and nucleoside reverse transcriptase inhibitor treatment regimens with stavudine, zalactabine, or didanosine did not significantly explain any additional model variation.

Conclusion: These findings are consistent with physiological research and provide evidence that analyzing multiple symptom change over time can provide a more accurate representation of an individual's symptom experience. When evaluating patients with muscle aches or numbness, particularly when both symptoms are present, an evaluation of fatigue should be considered. Similarly, if fatigue is reported, underlying physiological assessments for neuropathic symptoms and muscle aches may be considered.

PubMed Disclaimer

Conflict of interest statement

Disclosures

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Diagram of the Symptom Change Lagged effects Model

Similar articles

Cited by

References

    1. Ammassari A, Antinori A, Aloisi MS, et al. Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons. Psychosomatics. 2004;45(5):394–402. - PubMed
    1. Bonfanti P, Ricci E, Landonio S, et al. Predictors of protease inhibitor-associated adverse events. Biomed Pharmacother. 2001;55(6):321–323. - PubMed
    1. Catz SL, Kelly JA, Bogart LM, Benotsch EG, McAuliffe TL. Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychol. 200;19(2):124–133. - PubMed
    1. Holzemer WL. HIV and AIDS: the symptom experience. What cell counts and viral loads won’t tell you. Am J Nurs. 2002;102(4):48–52. - PubMed
    1. Vogl D, Rosenfeld B, Breitbart W, et al. Symptom prevalence, characteristics, and distress in AIDS outpatients. J Pain Symptom Manage. 1999;18(4):253–262. - PubMed

Publication types

MeSH terms

Substances